Zobrazeno 1 - 10
of 4 084
pro vyhledávání: ''
Autor:
Katarzyna Jozwiak, Annelies H. Boekhout, Christian U. Blank, G. Vreugdenhil, Ellen Kapiteijn, Karijn P M Suijkerbuijk, D Piersma, Geke A. P. Hospers, A.A.M. Van der Veldt, Marye J Boers-Sonderen, K.J. Janssen, L.V. van de Poll-Franse, A.J. ten Tije, J.W.B. de Groot, Maureen J.B. Aarts, Bart Neyns, Elisa A. Rozeman, Anne Rogiers, A.J.M. van den Eertwegh
Publikováno v:
Acta Oncologica, 60(1), 69-77. Informa Healthcare
Acta Oncologica, 60, 1, pp. 69-77
Acta Oncologica, 60, 69-77
Acta Oncologica, 60(1), 69-77. Routledge/Taylor & Francis Group
ACTA ONCOLOGICA, 60(1), 69-77. Taylor & Francis Ltd
Acta Oncologica, 60(1), 69-77. TAYLOR & FRANCIS LTD
Boekhout, A H, Rogiers, A, Jozwiak, K, Boers-Sonderen, M J, van den Eertwegh, A J, Hospers, G A, de Groot, J W B, Aarts, M J B, Kapiteijn, E, ten Tije, A J, Piersma, D, Vreugdenhil, G, van der Veldt, A A, Suijkerbuijk, K P M, Rozeman, E A, Neyns, B, Janssen, K J, van de Poll-Franse, L V & Blank, C U 2021, ' Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls ', Acta Oncologica, vol. 60, no. 1, pp. 69-77 . https://doi.org/10.1080/0284186X.2020.1818823
Acta Oncologica, 60, 1, pp. 69-77
Acta Oncologica, 60, 69-77
Acta Oncologica, 60(1), 69-77. Routledge/Taylor & Francis Group
ACTA ONCOLOGICA, 60(1), 69-77. Taylor & Francis Ltd
Acta Oncologica, 60(1), 69-77. TAYLOR & FRANCIS LTD
Boekhout, A H, Rogiers, A, Jozwiak, K, Boers-Sonderen, M J, van den Eertwegh, A J, Hospers, G A, de Groot, J W B, Aarts, M J B, Kapiteijn, E, ten Tije, A J, Piersma, D, Vreugdenhil, G, van der Veldt, A A, Suijkerbuijk, K P M, Rozeman, E A, Neyns, B, Janssen, K J, van de Poll-Franse, L V & Blank, C U 2021, ' Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls ', Acta Oncologica, vol. 60, no. 1, pp. 69-77 . https://doi.org/10.1080/0284186X.2020.1818823
Contains fulltext : 232050.pdf (Publisher’s version ) (Open Access) BACKGROUND: Checkpoint inhibitors have changed overall survival for patients with advanced melanoma. However, there is a lack of data on health-related quality of life (HRQoL) of l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd09e256f654f4b814df9e2ceaa80f7
https://hdl.handle.net/20.500.14017/61e967f1-5267-4479-89e5-66dfa5bcacc3
https://hdl.handle.net/20.500.14017/61e967f1-5267-4479-89e5-66dfa5bcacc3
Publikováno v:
Clinical toxicology
Dear Editor, Anticholinergic toxicity is a commonly encountered intoxication, typically following ingestion of drugs with prominent anticholinergic action. Peripheral symptoms include dry mouth and...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6edd5aa61d7949077fe5f957945094
https://biblio.vub.ac.be/vubir/rivastigmine-for-the-treatment-of-anticholinergic-delirium-following-severe-procyclidine-intoxication(47fc8084-dc25-4932-b49e-fca36ff6dd8c).html
https://biblio.vub.ac.be/vubir/rivastigmine-for-the-treatment-of-anticholinergic-delirium-following-severe-procyclidine-intoxication(47fc8084-dc25-4932-b49e-fca36ff6dd8c).html
Clostridioides difficile infection treatment guidelines adherence and comparison of treatment outcomes of the first, non-severe disease episode between oral metronidazole and vancomycin group: a single tertiary center retrospective study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0fd8abce99132f72bbd4cfc1e10db21
https://doi.org/10.1080/23744235.2019.1602285
https://doi.org/10.1080/23744235.2019.1602285
Autor:
Luis Sánchez-Alvarez, Ruth Navarro-Artieda, Josep Darbà, Javier Rejas-Gutiérrez, Antoni Sicras-Mainar, Maria Perez-Paramo
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs.To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2fa3c8ad87de3783e7cf62c74db1f09
http://hdl.handle.net/2445/133837
http://hdl.handle.net/2445/133837
Publikováno v:
Current Medical Research and Opinion. 32:1325-1334
The tyrosine kinase inhibitor (TKI) bosutinib has demonstrated activity in patients with advanced phase chronic myeloid leukemia (CML), but effects on health-related quality of life (HRQoL) remain unexplored. This study evaluated HRQoL in advanced CM
Publikováno v:
Expert Opinion on Pharmacotherapy. 17:885-888
Carbamazepine (CBZ) is one of the older antiepileptic drugs (AEDs), both in the US and worldwide. Neurologists and non-neurologists have become very familiar with its spectrum of efficacy, advantag...
Publikováno v:
Expert Opinion on Drug Safety. 15:911-923
The number of breast cancer long survivors has increased in the last few years. However, this increase in survival may be affected by the side effects of adjuvant breast cancer therapies. In this context cardiovascular toxicity is considered one of t
Autor:
Jennifer Gao, Sandra M. Swain
Publikováno v:
Expert Opinion on Drug Safety. 15:853-863
Introduction: Approximately twenty to thirty percent of newly diagnosed breast cancers are human epidermal growth factor receptor 2 (HER2) positive. The use of trastuzumab, and more recently pertuzumab, has significantly improved the progression free
Autor:
Susanna A. McColley
Publikováno v:
Expert Opinion on Drug Safety. 15:709-715
Ivacaftor is indicated for treatment of cystic fibrosis (CF) mediated by 10 mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene that causes gating or partial function abnormalities. In placebo-controlled and open-label st
Autor:
Bruno Fattizzo, Mariarita Sciumè, Ramona Cassin, Agostino Cortelezzi, Nicola Orofino, Gianluigi Reda
Publikováno v:
Expert Opinion on Drug Safety. 15:865-873
Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody (MoAb) with a higher affinity for CD20 epitope. It was approved by the United States Food and Drug Administration (FDA) in November 2013 for use in combination with chloram